CDMO Scale CorePharma operates 4 FDA- and DEA-registered facilities with 150,000 square feet and an annual production capacity of 5 billion dosage units, indicating robust manufacturing scale and potential for large contract manufacturing engagements.

End-to-End Capability As a concept to commercial CDMO offering development, analytical, clinical, and commercial manufacturing and packaging, CorePharma can be a single-source partner for clients seeking streamlined timelines and integrated project management.

Regulatory Strength A track record of regulatory excellence suggests reliability in navigating compliance and submissions, which is appealing to sponsors seeking minimize regulatory risk and accelerate time to market.

Cyber Risk Reported ransomware incident highlights a potential vulnerability; presenting a sales angle around enhanced cybersecurity, data protection services, and resilient IT/OT integration could be a differentiator when engaging risk-conscious clients.

Growth Potential Revenue range and mid-size employee base indicate a scalable partner with opportunities for expanded services, additional capacity, or regional expansion collaborations with mid-market pharma companies seeking reliable CDMO support.